Paclitaxel
證據等級: L5 | 預測適應症: 10 個
## 藥師評估報告
Paclitaxel 藥師筆記
一句話總結
Paclitaxel 為紫杉醇類抗腫瘤藥物，TxGNN 預測其對乳癌 (包括三陰性乳癌、雌激素受體陽性乳癌) 有治療潛力，此預測已獲大量 Phase III 臨床試驗證實，證據等級最高。
快速總覽
| 項目 | 內容 |
|---|---|
| 藥品名稱 | Paclitaxel (紫杉醇) |
| DrugBank ID | DB01229 |
| 台灣商品名 | 曲斯若凍晶注射劑、汰癌勝注射劑等 |
| 原適應症 | 卵巢癌、乳癌、非小細胞肺癌、胃癌、食道癌、頭頸癌、膀胱癌、子宮頸癌 |
| 預測新適應症 | 女性乳腺癌、hereditary breast ovarian cancer syndrome、estrogen-receptor negative breast cancer、hormone-resistant breast carcinoma、estrogen-receptor positive breast cancer、Ehrlich tumor carcinoma、bilateral breast carcinoma、breast carcinoma by gene expression profile、nipple carcinoma、ovarian clear cell adenocarcinoma |
| 證據等級 | L1 (多個 RCT) |
| TxGNN 預測分數 | 0.999+ |
預測適應症詳細分析
1. female breast carcinoma L1 100.00% 主要分析
為什麼這個預測合理？
### 機轉連結
- 微管穩定作用：Paclitaxel 結合 beta-tubulin 促進微管聚合並穩定微管，抑制有絲分裂，導致細胞凋亡。
- 免疫調節作用：最新研究顯示 paclitaxel 可調節腫瘤相關巨噬細胞 (TAM)，增強 PD-1 阻斷劑的療效。
- 克服荷爾蒙抗性：對於荷爾蒙治療無效的 ER+ 乳癌，化療仍是重要選項，paclitaxel 透過不依賴荷爾蒙受體的機制發揮作用。
臨床試驗
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT05244993 | PHASE2 | UNKNOWN | 42 | AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-l... |
| NCT07307911 | PHASE2 | RECRUITING | 50 | Neuroprotective Effects of Coenzyme Q10 in Paclitaxel-Induced Peripheral Neuropa... |
| NCT03329950 | PHASE1 | COMPLETED | 132 | A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Ad... |
| NCT05107674 | PHASE1 | RECRUITING | 345 | A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas... |
| NCT06636591 | NA | RECRUITING | 14 | A Prospective, Open-label, Single-center, Pilot Study of Neoadjuvant Chemotherap... |
| NCT00404404 | PHASE2 | UNKNOWN | 35 | Phase II Trial of Abraxane Administered on a Weekly Schedule in Combination With... |
| NCT05566457 | PHASE2 | UNKNOWN | 92 | Clinical Study of Huangshi Guizhi Wuwu Decoction in Improving the Paclitaxel-rel... |
| NCT00054028 | PHASE1, PHASE2 | COMPLETED | 31 | A Phase I/II Study of Suramin in Combination With Paclitaxel in Advanced (Stage ... |
| NCT00019019 | PHASE1 | COMPLETED | 70 | A PHASE I STUDY OF THE COMBINATION OF CAI AND PACLITAXEL IN ADULT PATIENTS WITH ... |
| NCT05809895 | PHASE2 | WITHDRAWN | 0 | AdvanTIG-211: A Randomized, Double-blind, Placebo-controlled, Phase II Study Eva... |
| NCT05207709 | PHASE3 | ACTIVE_NOT_RECRUITING | 456 | A Phase III, Multicenter, Open-label Study of Ribociclib vs. Palbociclib in Pati... |
| NCT00589238 | PHASE2 | TERMINATED | 16 | Randomised Phase II Trial of Neoadjuvant Weekly Paclitaxel Plus Carboplatin Comp... |
| NCT03022162 | N/A | COMPLETED | 150 | Prevalence of Paclitaxel Induced CIPN-Related Pain and CIPN in Indian Patients W... |
| NCT02549534 | N/A | COMPLETED | 29 | Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer |
| NCT00561119 | PHASE3 | COMPLETED | 326 | Phase III, Multicenter, Randomized Trial of Maintenance Versus Observation After... |
| NCT00472693 | PHASE2 | COMPLETED | 5 | A Phase II Trial of Bevacizumab and ABI-007 (Abraxane) as Second-line Therapy in... |
| NCT01147016 | PHASE2 | TERMINATED | 8 | A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (A... |
| NCT00544167 | NA | COMPLETED | 45 | A Pilot Study of Adjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxe... |
| NCT03799679 | PHASE4 | UNKNOWN | 60 | Nanoparticle Albumin-Bound Paclitaxel Followed by Dose-Intensive Epirubicin in C... |
| NCT00006459 | PHASE3 | COMPLETED | N/A | Phase III Study of Gemcitabine Plus Paclitaxel Versus Paclitaxel in Patients Wit... |
| NCT03644342 | PHASE1, PHASE2 | TERMINATED | 4 | Phase I/II Study of Niraparib With Radiotherapy for Treatment of Metastatic Inva... |
| NCT00934895 | PHASE1, PHASE2 | TERMINATED | 27 | Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Advanced or... |
| NCT02954055 | PHASE2 | COMPLETED | 140 | A Randomized Phase II Trial of Metronomic Oral Vinorelbine Plus Cyclophosphamide... |
| NCT00001383 | PHASE1 | COMPLETED | 52 | A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC ... |
| NCT00513292 | PHASE3 | COMPLETED | 280 | A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed ... |
| NCT04126525 | PHASE2 | ACTIVE_NOT_RECRUITING | 53 | NeoAdjuvant Trastuzumab/ Pyrotinib Plus Weekly Paclitaxel/Cisplatin in HER2-posi... |
| NCT01881230 | PHASE2, PHASE3 | COMPLETED | 191 | A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxe... |
| NCT00281658 | PHASE3 | COMPLETED | 444 | A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of ... |
| NCT00542451 | PHASE2 | COMPLETED | 406 | A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-P... |
| NCT00587925 | NA | COMPLETED | 7 | A Pilot Study of Bone Mineral Density in Postmenopausal Women After Treatment fo... |
| NCT02125019 | N/A | COMPLETED | 62 | Longitudinal Evaluation of Taxane Induced Neuropathy in Early Stage Breast Cance... |
| NCT00499291 | NA | WITHDRAWN | 0 | Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Na... |
| NCT00272987 | PHASE3 | TERMINATED | 63 | A Randomized, Double Blind, Placebo-Controlled, Multicenter, Phase III Study Com... |
| NCT02071862 | PHASE1 | COMPLETED | 210 | Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase... |
| NCT06176339 | PHASE2 | ACTIVE_NOT_RECRUITING | 70 | "Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemothe... |
| NCT01454479 | PHASE1 | UNKNOWN | 24 | A Phase I Study of Lapatinib (Tykerb) Plus Ixabepilone (Ixempra) as 2nd-line Tre... |
| NCT00311636 | PHASE3 | COMPLETED | 280 | Prevention of Chemotherapy-induced Menopause by Temporary Ovarian Suppression Wi... |
| NCT04644068 | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING | 702 | A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Toler... |
| NCT00954174 | PHASE3 | UNKNOWN | 637 | A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Pl... |
| NCT03725059 | PHASE3 | ACTIVE_NOT_RECRUITING | 1240 | A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in C... |
| NCT01583426 | PHASE3 | COMPLETED | 1229 | A Randomized Phase III Trial Comparing Nanoparticle-based Paclitaxel With Solven... |
| NCT07074106 | PHASE2 | NOT_YET_RECRUITING | 40 | DespaTIL Study: A Phase II Trial of De-escalated Neoadjuvant Chemotherapy for Ea... |
| NCT01094184 | PHASE4 | COMPLETED | 49 | Open-Label Study of Bevacizumab (Avastin®) and Taxane Monotherapy for the First-... |
| NCT07103447 | PHASE2 | NOT_YET_RECRUITING | 54 | A Prospective, Multicenter, Single-Arm Study of AK112 in Combination With Albumi... |
| NCT02225652 | PHASE2 | COMPLETED | 11 | A Phase II Study of Dose Density Regimen With Fluorouracil, Epirubicin and Cyclo... |
| NCT00262847 | PHASE3 | COMPLETED | 1873 | A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin ... |
| NCT04677816 | PHASE2 | RECRUITING | 50 | Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response ... |
| NCT05143970 | PHASE1 | RECRUITING | 27 | A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination ... |
| NCT01405924 | PHASE2 | TERMINATED | 111 | EMEND® IV In Salvage Treatment of Chemotherapy-Induced Vomiting |
| NCT03601897 | PHASE1, PHASE2 | TERMINATED | 177 | An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combina... |
相關文獻
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 31783552 | 2019 | Article | Biomolecules | Paclitaxel's Mechanistic and Clinical Effects on Breast Cancer. |
| 39009452 | 2024 | Article | Journal for immunotherapy of c | Novel insights into paclitaxel's role on tumor-associated macrophages in enhanci... |
| 9282422 | 1997 | Article | Drug and therapeutics bulletin | Paclitaxel and docetaxel in breast and ovarian cancer. |
| 24823476 | 2014 | Article | Nature communications | Enriched variations in TEKT4 and breast cancer resistance to paclitaxel. |
| 31515668 | 2019 | Article | Cancer chemotherapy and pharma | Downregulation of SRSF3 by antisense oligonucleotides sensitizes oral squamous c... |
| 28126294 | 2017 | Article | International journal of radia | Internal Mammary Misfortune. |
| 11147586 | 2000 | Article | Cancer | Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adj... |
| 39317691 | 2024 | Article | Chemical biology & drug design | Unveiling the Therapeutic Potential of Paclitaxel Combinations Against Breast Ca... |
| 36964413 | 2023 | Article | Human cell | TIPE2 sensitizes breast cancer cells to paclitaxel by suppressing drug-induced a... |
| 36221929 | 2023 | Article | Journal of biomedical material | Cerium oxide nanoparticles exert antitumor effects and enhance paclitaxel toxici... |
| 10928395 | 2000 | Article | The Annals of pharmacotherapy | Cyclosporine-induced anaphylaxis. |
| 20665703 | 2011 | Article | Journal of cellular physiology | ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast car... |
| 11745249 | 2001 | Article | Cancer | Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. |
| 32461977 | 2020 | Article | BioMed research international | Efficacy of Neoadjuvant Chemotherapy with Epirubicin and Cyclophosphamide and We... |
| 10791395 | 2000 | Article | Lancet (London, England) | The taxanes: an update. |
| 22353935 | 2012 | Article | Cancer biology & therapy | Overexpression of centrosomal protein Nlp confers breast carcinoma resistance to... |
| 39400682 | 2024 | Article | Medical oncology (Northwood, L | Glycolytic pathway analysis and gene expression profiles of combination of aloe ... |
| 39471010 | 2024 | Article | Asian Pacific journal of cance | Molecular Docking and Pharmacokinetic Profiling of Nab-paclitaxel as Advanced Ch... |
| 10517345 | 1999 | Article | Breast cancer research and tre | Schedule-dependent interactions between vinorelbine and paclitaxel in human carc... |
| 16435143 | 2006 | Article | Journal of cancer research and | Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy f... |
2. estrogen-receptor negative breast cancer L1 99.91%
臨床試驗（50 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT01777932 | N/A | COMPLETED | 220 | A Multicenter, Single-arm, Observational Study Describing the Clinical Benefits ... |
| NCT04132817 | PHASE1 | COMPLETED | 12 | A Phase 1 Multi-Targeted Study to Promote Anti-Tumor Immunity in ER Positive, HE... |
| NCT02734290 | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING | 29 | A Pilot and Phase II Study to Assess the Safety, Tolerability and Efficacy of Pe... |
| NCT04152057 | PHASE1, PHASE2 | UNKNOWN | 20 | A Single-arm, Exploratory Clinical Study of Pyrotinib Maleate Tablets Combined W... |
| NCT01897441 | NA | TERMINATED | 31 | Prospective Tissue Collection in Breast Cancer Patients Receiving Preoperative S... |
| NCT01147016 | PHASE2 | TERMINATED | 8 | A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (A... |
| NCT03725436 | PHASE1 | ACTIVE_NOT_RECRUITING | 35 | A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 A... |
| NCT01565499 | PHASE2 | COMPLETED | 83 | Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant... |
| NCT02954055 | PHASE2 | COMPLETED | 140 | A Randomized Phase II Trial of Metronomic Oral Vinorelbine Plus Cyclophosphamide... |
| NCT01816594 | PHASE2 | COMPLETED | 50 | NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Ran... |
| NCT04770272 | PHASE2 | TERMINATED | 442 | An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cance... |
| NCT01881230 | PHASE2, PHASE3 | COMPLETED | 191 | A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxe... |
| NCT01421472 | PHASE2 | COMPLETED | 196 | A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negat... |
| NCT04247126 | PHASE1 | COMPLETED | 105 | A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients... |
| NCT00773695 | PHASE2 | COMPLETED | 150 | A Multicenter, Randomized, Phase II Clinical Trial to Evaluate the Effect of Ava... |
| NCT05325632 | PHASE2 | RECRUITING | 53 | A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed De... |
| NCT02598310 | PHASE2 | TERMINATED | 30 | Phase II Study of Neoadjuvant Nab-paclitaxel (PTX) and Trastuzumab for ER Negati... |
| NCT00003440 | PHASE3 | COMPLETED | 580 | A Phase III Study of Paclitaxel Via Weekly 1 Hour Infusion Versus Standard 3 Hou... |
| NCT03725059 | PHASE3 | ACTIVE_NOT_RECRUITING | 1240 | A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in C... |
| NCT03554109 | PHASE2 | WITHDRAWN | 0 | An Open-Label Randomized Phase 2 Trial Of The NANT NEOADJUVANT Triple-Negative B... |
| NCT01818063 | PHASE2 | COMPLETED | 9 | An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response... |
| NCT04243616 | PHASE2 | ACTIVE_NOT_RECRUITING | 36 | Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast C... |
| NCT01094184 | PHASE4 | COMPLETED | 49 | Open-Label Study of Bevacizumab (Avastin®) and Taxane Monotherapy for the First-... |
| NCT00070564 | PHASE3 | ACTIVE_NOT_RECRUITING | 3294 | Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed... |
| NCT06746870 | PHASE2 | NOT_YET_RECRUITING | 148 | A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and P... |
| NCT02685306 | PHASE2 | WITHDRAWN | 0 | A Phase II Study to Determine the Pathological Complete Response Rate and Immuno... |
| NCT04443348 | PHASE2 | ACTIVE_NOT_RECRUITING | 120 | P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Lo... |
| NCT02530489 | PHASE2 | COMPLETED | 37 | Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL32... |
| NCT01303679 | PHASE3 | TERMINATED | 117 | Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy W... |
| NCT03726879 | PHASE3 | COMPLETED | 454 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Eval... |
| NCT06656624 | PHASE2 | RECRUITING | 190 | Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Ch... |
| NCT02483767 | PHASE3 | COMPLETED | 98 | Gonadotropin-Releasing Hormone Agonist for the Preservation of Ovarian Function ... |
| NCT06964906 | PHASE2 | RECRUITING | 140 | A Randomized, Open-Label, Blinded Endpoint Study of High-Intensity Focused Ultra... |
| NCT05302336 | PHASE4 | UNKNOWN | 402 | A Randomized Controlled Study of AC (Doxorubicin Hydrochloride Liposome/Cyclopho... |
| NCT05594095 | PHASE2 | RECRUITING | 620 | Precision Platform Study of HR+/ HER2-advanced Breast Cancer Based on SNF Typing... |
| NCT04602117 | PHASE1 | WITHDRAWN | 0 | ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarma... |
| NCT01307891 | PHASE2 | COMPLETED | 64 | An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound ... |
| NCT00542191 | PHASE2 | TERMINATED | 30 | Phase II Trial of Neoadjuvant Metronomic Chemotherapy in Triple-Negative Breast ... |
| NCT01276496 | PHASE1 | COMPLETED | 13 | A Phase I, Open Label, Dose Escalation Study of the Safety, Tolerability and Pha... |
| NCT01698281 | PHASE2 | TERMINATED | 7 | A Randomized Phase 2 Trial of AEZS-108 in Chemotherapy Refractory Triple Negativ... |
| NCT00856492 | PHASE2 | COMPLETED | 215 | A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab... |
| NCT03841747 | PHASE2 | WITHDRAWN | 0 | A Phase II, Randomized Study of Paclitaxel Weekly Plus Pembrolizumab Versus Pacl... |
| NCT00667251 | PHASE3 | COMPLETED | 652 | A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy With Lapa... |
| NCT04745975 | PHASE2 | UNKNOWN | 100 | GUided Treatment Based on Mini-PDX in metastaTIc refractOry Triple Negative Brea... |
| NCT05981014 | PHASE1, PHASE2 | RECRUITING | 196 | An Open-Label Phase I/II Study of Autologous Tumor-Draining Lymph Node-Derived L... |
| NCT03387085 | PHASE1, PHASE2 | TERMINATED | 9 | NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrat... |
| NCT01625286 | PHASE1, PHASE2 | COMPLETED | 148 | A Phase I/II Study of AZD5363 Combined With Paclitaxel in Patients With Advanced... |
| NCT06121570 | PHASE1 | RECRUITING | 24 | Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neo... |
| NCT01159236 | NA | WITHDRAWN | 0 | Molecular Triaging of Newly Diagnosed Breast Cancer for Preoperative Therapies |
| NCT02603679 | PHASE2 | ACTIVE_NOT_RECRUITING | 181 | PREDIX Luminal B - Neoadjuvant Response-guided Treatment of ER Positive Tumors W... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 38771995 | 2024 | Article | Journal of clinical oncology : | Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combinat... |
| 33015734 | 2021 | Article | Cancer immunology, immunothera | Pembrolizumab and atezolizumab in triple-negative breast cancer. |
| 37440239 | 2023 | Article | JAMA oncology | Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs W... |
| 37526149 | 2023 | Article | Future oncology (London, Engla | TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or met... |
| 39838117 | 2025 | Article | Nature medicine | Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cance... |
| 39631485 | 2024 | Article | Pharmacological research | Targeted and cytotoxic inhibitors used in the treatment of breast cancer. |
| 24523301 | 2014 | Article | Molecular cancer therapeutics | Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast... |
| 31786121 | 2020 | Article | The Lancet. Oncology | Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, local... |
| 28135148 | 2017 | Article | Journal of clinical oncology : | Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residua... |
| 29604436 | 2018 | Article | Pharmacological research | Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatm... |
| 40049198 | 2025 | Article | The Lancet. Oncology | Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple... |
| 36982940 | 2023 | Article | International journal of molec | Estrogen Receptor β4 Regulates Chemotherapy Resistance and Induces Cancer Stem C... |
| 36241702 | 2023 | Article | Cancer gene therapy | Nogo-B receptor increases glycolysis and the paclitaxel resistance of estrogen r... |
| 34911787 | 2022 | Article | Cancer research | Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic ... |
| 15023242 | 2004 | Article | Clinical breast cancer | Paclitaxel improves the prognosis in estrogen receptor negative inflammatory bre... |
| 35795050 | 2022 | Article | Frontiers in oncology | Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer. |
| 30860570 | 2019 | Article | Annals of oncology : official | BEECH: a dose-finding run-in followed by a randomised phase II study assessing t... |
| 39644440 | 2025 | Article | Breast cancer (Tokyo, Japan) | Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for earl... |
| 30802822 | 2019 | Article | Breast (Edinburgh, Scotland) | Randomized phase II study evaluating weekly oral vinorelbine versus weekly pacli... |
| 35976445 | 2023 | Article | Journal of cancer research and | Triple negative breast cancer: approved treatment options and their mechanisms o... |
3. hormone-resistant breast carcinoma L1 99.91%
臨床試驗（14 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT03285607 | PHASE1 | WITHDRAWN | 0 | Phase I Study of MCS110 Combined With Neoadjuvant Dose-Dense Doxorubicin, Cyclop... |
| NCT02616848 | PHASE1 | UNKNOWN | 1 | Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-neg... |
| NCT04771871 | PHASE2 | UNKNOWN | 42 | Treatment Response and microRNA Profiles in Triple Negative Breast Cancer Patien... |
| NCT02603679 | PHASE2 | ACTIVE_NOT_RECRUITING | 181 | PREDIX Luminal B - Neoadjuvant Response-guided Treatment of ER Positive Tumors W... |
| NCT01031446 | PHASE1, PHASE2 | COMPLETED | 55 | A Phase Ib/II Study of Cisplatin, Paclitaxel, and RAD001 in Patients With Metast... |
| NCT04158362 | PHASE3 | ACTIVE_NOT_RECRUITING | 180 | Open-label, Randomized, Multicenter, Phase III Study, Comparing Standard Chemoth... |
| NCT07327021 | PHASE2 | RECRUITING | 54 | NOGA: Neoadjuvant Treatment Optimization Via MRI-Guided De-Escalation in Stage I... |
| NCT03925233 | N/A | UNKNOWN | 300 | Sensitivity Detection and Drug Resistance Mechanism of Breast Cancer Therapeutic... |
| NCT03179904 | PHASE2 | ACTIVE_NOT_RECRUITING | 19 | Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Comb... |
| NCT01779479 | PHASE2 | COMPLETED | 333 | Randomized, Open-label, Phase II Study Comparing the Efficacy and the Safety of ... |
| NCT05429684 | PHASE3 | UNKNOWN | 120 | Precise Targeted Therapy for Refractory HER2 Positive Advanced Breast Cancer Bas... |
| NCT03358004 | PHASE2 | TERMINATED | 4 | An International, Multicenter, Phase II, Randomized, Parallel-arm Trial Investig... |
| NCT06734533 | N/A | RECRUITING | 80 | A New Option for Post-CDK4/6is Resistance Era: Multicenter Real-world Study of A... |
| NCT03444025 | PHASE2 | UNKNOWN | 180 | Prospective Phase II Randomized Trial of Evaluating the Effect of Adding LHRH An... |
相關文獻（9 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 9071337 | 1997 | Article | Seminars in oncology | Response to estramustine phosphate and paclitaxel in patients with advanced brea... |
| 8091238 | 1994 | Article | Seminars in oncology | Salvage chemotherapy of breast cancer. |
| 34781168 | 2021 | Article | European journal of cancer (Ox | TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301... |
| 7481851 | 1995 | Article | Seminars in oncology | Management of breast cancer: status and future trends. |
| 9374083 | 1997 | Article | Seminars in oncology | Chemotherapy of breast cancer: a historical perspective. |
| 12353824 | 2002 | Article | Breast cancer research and tre | The role of EGFR-directed therapy in the treatment of breast cancer. |
| 17475221 | 2007 | Article | Biochemical pharmacology | Quinolone analogue inhibits tubulin polymerization and induces apoptosis via Cdk... |
| 20462978 | 2010 | Article | Japanese journal of clinical o | Randomized study of taxane versus TS-1 in women with metastatic or recurrent bre... |
| 27306814 | 2016 | Article | Gan to kagaku ryoho. Cancer & | [An Elderly Patient with Metastatic Breast Cancer Who Developed Severe Adverse E... |
4. estrogen-receptor positive breast cancer L1 99.91%
臨床試驗（50 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT01777932 | N/A | COMPLETED | 220 | A Multicenter, Single-arm, Observational Study Describing the Clinical Benefits ... |
| NCT06202261 | PHASE1, PHASE2 | RECRUITING | 154 | A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of TQB2930 for ... |
| NCT04132817 | PHASE1 | COMPLETED | 12 | A Phase 1 Multi-Targeted Study to Promote Anti-Tumor Immunity in ER Positive, HE... |
| NCT04152057 | PHASE1, PHASE2 | UNKNOWN | 20 | A Single-arm, Exploratory Clinical Study of Pyrotinib Maleate Tablets Combined W... |
| NCT01897441 | NA | TERMINATED | 31 | Prospective Tissue Collection in Breast Cancer Patients Receiving Preoperative S... |
| NCT01147016 | PHASE2 | TERMINATED | 8 | A Phase II Study of Anti-CD3 x Anti-HER2/Neu (Her2Bi) Armed Activated T Cells (A... |
| NCT03725436 | PHASE1 | ACTIVE_NOT_RECRUITING | 35 | A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 A... |
| NCT01565499 | PHASE2 | COMPLETED | 83 | Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant... |
| NCT02954055 | PHASE2 | COMPLETED | 140 | A Randomized Phase II Trial of Metronomic Oral Vinorelbine Plus Cyclophosphamide... |
| NCT01816594 | PHASE2 | COMPLETED | 50 | NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Ran... |
| NCT01421472 | PHASE2 | COMPLETED | 196 | A Randomized, Phase 2 Trial of Preoperative MM-121 With Paclitaxel in HER2-negat... |
| NCT04247126 | PHASE1 | COMPLETED | 105 | A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients... |
| NCT05325632 | PHASE2 | RECRUITING | 53 | A Phase II Study of Human Epidermal Growth Factor Receptor 2 (HER-2) Directed De... |
| NCT00407888 | PHASE2 | COMPLETED | 60 | Adjuvant Therapy for High-Risk Localized Breast Cancer Using Weekly Adriamycin +... |
| NCT02598310 | PHASE2 | TERMINATED | 30 | Phase II Study of Neoadjuvant Nab-paclitaxel (PTX) and Trastuzumab for ER Negati... |
| NCT03725059 | PHASE3 | ACTIVE_NOT_RECRUITING | 1240 | A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in C... |
| NCT04243616 | PHASE2 | ACTIVE_NOT_RECRUITING | 36 | Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast C... |
| NCT00070564 | PHASE3 | ACTIVE_NOT_RECRUITING | 3294 | Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed... |
| NCT04443348 | PHASE2 | ACTIVE_NOT_RECRUITING | 120 | P-RAD: A Randomized Study of Preoperative Chemotherapy, Pembrolizumab and No, Lo... |
| NCT01303679 | PHASE3 | TERMINATED | 117 | Phase III Randomized Multicenter Trial Comparing Continued Maintenance Therapy W... |
| NCT03726879 | PHASE3 | COMPLETED | 454 | A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Eval... |
| NCT06964906 | PHASE2 | RECRUITING | 140 | A Randomized, Open-Label, Blinded Endpoint Study of High-Intensity Focused Ultra... |
| NCT05302336 | PHASE4 | UNKNOWN | 402 | A Randomized Controlled Study of AC (Doxorubicin Hydrochloride Liposome/Cyclopho... |
| NCT01491737 | PHASE2 | COMPLETED | 258 | A Randomized, Two-Arm, Open-Label, Multicenter Phase II Trial Assessing the Effi... |
| NCT05594095 | PHASE2 | RECRUITING | 620 | Precision Platform Study of HR+/ HER2-advanced Breast Cancer Based on SNF Typing... |
| NCT04602117 | PHASE1 | WITHDRAWN | 0 | ISPY-P1.01: Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarma... |
| NCT02654119 | PHASE2 | COMPLETED | 20 | A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclit... |
| NCT00856492 | PHASE2 | COMPLETED | 215 | A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab... |
| NCT03841747 | PHASE2 | WITHDRAWN | 0 | A Phase II, Randomized Study of Paclitaxel Weekly Plus Pembrolizumab Versus Pacl... |
| NCT00667251 | PHASE3 | COMPLETED | 652 | A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy With Lapa... |
| NCT01625286 | PHASE1, PHASE2 | COMPLETED | 148 | A Phase I/II Study of AZD5363 Combined With Paclitaxel in Patients With Advanced... |
| NCT01159236 | NA | WITHDRAWN | 0 | Molecular Triaging of Newly Diagnosed Breast Cancer for Preoperative Therapies |
| NCT02603679 | PHASE2 | ACTIVE_NOT_RECRUITING | 181 | PREDIX Luminal B - Neoadjuvant Response-guided Treatment of ER Positive Tumors W... |
| NCT07187674 | NA | NOT_YET_RECRUITING | 20 | Single Arm, Prospective, Small Sample, Exploratory Clinical Study on the Neoadju... |
| NCT00785291 | PHASE3 | COMPLETED | 799 | A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticl... |
| NCT05296746 | PHASE2 | RECRUITING | 1100 | Neoadjuvant and Adjuvant Ribociclib and Endocrine Therapy for Clinically High-ri... |
| NCT06474988 | N/A | RECRUITING | 150 | Characterization of Biophysical and Mechanical Parameters on the Skin of Subject... |
| NCT00005970 | PHASE3 | COMPLETED | 3436 | Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Pacl... |
| NCT00194792 | PHASE2 | TERMINATED | 28 | Neoadjuvant Complete Hormonal Blockade Followed by Neoadjuvant Chemotherapy for ... |
| NCT00063999 | PHASE3 | COMPLETED | 1381 | Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus ... |
| NCT01830244 | PHASE2 | UNKNOWN | 60 | Tailored Neoadjuvant Epirubicin and Cyclophosphamide (EC) and Nanoparticle Album... |
| NCT05831553 | N/A | UNKNOWN | 100 | Evaluation of a Tissue Immune Profile (TIP) in Patients Affected by Metastatic T... |
| NCT04038489 | PHASE2 | WITHDRAWN | 0 | COX Inhibition and Biomarkers of Response During Neoadjuvant Chemoendocrine Ther... |
| NCT06099769 | PHASE2 | RECRUITING | 201 | A RANDOMIZED, PHASE II STUDY OF ENZALUTAMIDE, ENZALUTAMIDE WITH MIFEPRISTONE, an... |
| NCT02476955 | PHASE1 | TERMINATED | 41 | An Open-label Phase 1b Study of ARQ 092 in Combination With Other Antineoplastic... |
| NCT06500208 | PHASE2 | RECRUITING | 48 | An Open-label, One-arm Phase II Study of Adebrelimab Combined With Neoadjuvant C... |
| NCT04753177 | PHASE2, PHASE3 | UNKNOWN | 120 | The Neoadjuvant Combined Hormone Therapy in Premenopausal Women With Locally Adv... |
| NCT02018458 | PHASE1, PHASE2 | COMPLETED | 10 | Pilot Safety Trial of Preoperative Chemotherapy Combined With Dendritic Cell Vac... |
| NCT00003992 | PHASE2 | COMPLETED | 200 | Pilot Trial of Paclitaxel-Herceptin Adjuvant Therapy for Early Stage Breast Canc... |
| NCT00455533 | PHASE2 | COMPLETED | 384 | A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by I... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 38771995 | 2024 | Article | Journal of clinical oncology : | Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combinat... |
| 37440239 | 2023 | Article | JAMA oncology | Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs W... |
| 30413379 | 2018 | Article | The Lancet. Oncology | Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual ... |
| 39838117 | 2025 | Article | Nature medicine | Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2- breast cance... |
| 39631485 | 2024 | Article | Pharmacological research | Targeted and cytotoxic inhibitors used in the treatment of breast cancer. |
| 33015734 | 2021 | Article | Cancer immunology, immunothera | Pembrolizumab and atezolizumab in triple-negative breast cancer. |
| 34014249 | 2021 | Article | JAMA oncology | Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines ... |
| 28135148 | 2017 | Article | Journal of clinical oncology : | Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residua... |
| 29604436 | 2018 | Article | Pharmacological research | Investigational chemotherapy and novel pharmacokinetic mechanisms for the treatm... |
| 28945833 | 2017 | Article | Annals of oncology : official | De-escalation strategies in HER2-positive early breast cancer (EBC): final analy... |
| 31786121 | 2020 | Article | The Lancet. Oncology | Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, local... |
| 40049198 | 2025 | Article | The Lancet. Oncology | Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple... |
| 36241702 | 2023 | Article | Cancer gene therapy | Nogo-B receptor increases glycolysis and the paclitaxel resistance of estrogen r... |
| 24523301 | 2014 | Article | Molecular cancer therapeutics | Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast... |
| 34911787 | 2022 | Article | Cancer research | Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic ... |
| 41315271 | 2025 | Article | Nature communications | Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pe... |
| 30860570 | 2019 | Article | Annals of oncology : official | BEECH: a dose-finding run-in followed by a randomised phase II study assessing t... |
| 30802822 | 2019 | Article | Breast (Edinburgh, Scotland) | Randomized phase II study evaluating weekly oral vinorelbine versus weekly pacli... |
| 32013102 | 2020 | Article | Cancers | Effect of Estrogen Receptor Status on Circulatory Immune and Metabolomics Profil... |
| 37622644 | 2023 | Article | Danish medical journal | Atezolizumab and nab-paclitaxel for advanced breast cancer in Danish real-world ... |
5. Ehrlich tumor carcinoma L2 99.91%
臨床試驗（1 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT04885270 | PHASE3 | UNKNOWN | 50 | Phase III Clinical Trial of Intravenous Paclitaxel Plus Intraperitoneal Cisplati... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 30342146 | 2019 | Article | International journal of biolo | Acylated chitosan anchored paclitaxel loaded liposomes: Pharmacokinetic and biod... |
| 31002367 | 2019 | Article | Oncology reports | Dietary baker's yeast sensitizes Ehrlich mammary adenocarcinoma to paclitaxel in... |
| 27426109 | 2016 | Article | International journal of pharm | Heparin modification enhances the delivery and tumor targeting of paclitaxel-loa... |
| 26500095 | 2016 | Article | Tumour biology : the journal o | The combination of thymoquinone and paclitaxel shows anti-tumor activity through... |
| 17385543 | 2007 | Article | Acta biologica Hungarica | Evaluation of the effect of paclitaxel, epirubicin and tamoxifen by cell kinetic... |
| 26792072 | 2016 | Article | Radiation oncology (London, En | Second-line treatment of recurrent HNSCC: tumor debulking in combination with hi... |
| 28950656 | 2017 | Article | Biomedicine & pharmacotherapy | Oxamate potentiates taxol chemotherapeutic efficacy in experimentally-induced so... |
| 33338480 | 2021 | Article | Experimental cell research | Antineoplastic activity of Salmonella Typhimurium outer membrane nanovesicles. |
| 26255673 | 2016 | Article | Anti-cancer agents in medicina | Paclitaxel Loaded Nanoliposomes in Thermosensitive Hydrogel: A Dual Approach for... |
| 28063824 | 2017 | Article | Journal of pharmaceutical scie | Development of Safe and Potent Oil-in-Water Emulsion of Paclitaxel to Treat Peri... |
| 35716981 | 2022 | Article | International journal of pharm | Effects of particle size and release property of paclitaxel-loaded nanoparticles... |
| 27367621 | 2016 | Article | Nutrition and cancer | Enhancing the Apoptotic Effect of a Low Dose of Paclitaxel on Tumor Cells in Mic... |
| 24369111 | 2014 | Article | Current drug safety | Anti-cancer, pharmacokinetic and biodistribution studies of cremophor el free al... |
| 22809646 | 2012 | Article | Biomaterials | Paclitaxel loaded PEGylated gleceryl monooleate based nanoparticulate carriers i... |
| 31628941 | 2020 | Article | Chemico-biological interaction | Inhibition of aldehyde dehydrogenase-1 and p-glycoprotein-mediated multidrug res... |
| 26528585 | 2015 | Article | ACS applied materials & interf | pH-Sensitive Biocompatible Nanoparticles of Paclitaxel-Conjugated Poly(styrene-c... |
| 10731049 | 2000 | Article | Naunyn-Schmiedeberg's archives | Differential alteration of cisplatin cytotoxicity and myelotoxicity by the pacli... |
| 27381609 | 2016 | Article | In vivo (Athens, Greece) | Apoptosis-inducing Effect of a Palladium(II) Complex-[PdCl(terpy)](sac).2H2O] on... |
| 25750302 | 2015 | Article | Anticancer research | Anticancer effect of a novel palladium-saccharinate complex of terpyridine by in... |
| 29161917 | 2018 | Article | Integrative cancer therapies | Baker's Yeast Sensitizes Metastatic Breast Cancer Cells to Paclitaxel In Vitro. |
6. bilateral breast carcinoma L2 99.89%
臨床試驗（5 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT02364726 | NA | COMPLETED | 28 | Acupuncture to Reduce Chemotherapy-induced Peripheral Neuropathy Severity During... |
| NCT04461977 | NA | COMPLETED | 60 | Acupuncture for Treatment of Peripheral Neuropathy Induced by Neoadjuvant or Adj... |
| NCT02457039 | NA | COMPLETED | 93 | An Assessor-Blinded, Randomised Controlled Trial of Acupuncture to Prevent Chemo... |
| NCT03873272 | NA | COMPLETED | 63 | Randomized Controlled Selection Trial of Cryotherapy vs. Compression Therapy for... |
| NCT05861830 | PHASE3 | RECRUITING | 80 | An Exploratory Study on Predicting the Efficacy of Dalpiciclib in Combination Wi... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 40690248 | 2025 | Article | JAMA | Ovarian Cancer: A Review. |
| 36068624 | 2022 | Article | International journal of retin | Bilateral intermediate uveitis following treatment with paclitaxel in a patient ... |
| 36335424 | 2022 | Article | The American journal of case r | Gynecomastia and Malignancy: A Case of Male Invasive Ductal Breast Carcinoma Tre... |
| 25978147 | 2017 | Article | Journal of chemotherapy (Flore | Paclitaxel-induced pneumonitis in patients with breast cancer: case series and r... |
| 11876386 | 2002 | Article | European journal of gynaecolog | Primary breast carcinoma of the vulva: case report and review of literature. |
| 38741768 | 2024 | Article | Frontiers in medicine | Untypical bilateral breast cancer with peritoneal fibrosis on 18F-FDG PET/CT: ca... |
| 38283858 | 2024 | Article | Frontiers in oncology | Bilateral inflammatory recurrence of HER-2 positive breast cancer: a unique case... |
| 15507181 | 2004 | Article | Clinical breast cancer | Paclitaxel chemotherapy in a pregnant patient with bilateral breast cancer. |
| 41323054 | 2025 | Article | Case reports in oncology | Synchronous Bilateral Breast Cancer with Heterogeneous Histology: Invasive Ducta... |
| 12603378 | 2003 | Article | The breast journal | Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: feasib... |
| 18796377 | 2008 | Article | Clinical & translational oncol | Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: p... |
| 38304030 | 2023 | Article | Frontiers in oncology | Case report: Urothelial injury in a female with breast cancer: a rare adverse ev... |
| 35985745 | 2022 | Article | BMJ case reports | First report of bilateral synchronous male accessory breast cancer. |
| 39401811 | 2024 | Article | Zhongguo zhen jiu = Chinese ac | [Electroacupuncture with different frequencies for paclitaxel-induced peripheral... |
| 35022341 | 2022 | Article | Internal medicine (Tokyo, Japa | Bilateral Inflammatory Breast Cancer That Developed Two Years after Treatment fo... |
| 24423958 | 2014 | Article | Gan to kagaku ryoho. Cancer & | [A case of carcinomatous cardiac tamponade caused by breast cancer treated with ... |
| 15550852 | 2004 | Article | Breast cancer (Tokyo, Japan) | Successful combination therapy with trastuzumab and Paclitaxel for adriamycin- a... |
| 26869049 | 2016 | Article | The Lancet. Oncology | Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for e... |
| 27668497 | 2016 | Article | Optometry and vision science : | Bilateral Corneal Epithelial Lesions Associated with Paclitaxel. |
| 8649555 | 1996 | Article | Neurology | Transient encephalopathy after paclitaxel (Taxol) infusion. |
7. breast carcinoma by gene expression profile L1 99.89%
臨床試驗（45 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT02628132 | PHASE1, PHASE2 | COMPLETED | 22 | Study of the Safety, Tolerability and Efficacy of the Investigational Anti PD-L1... |
| NCT00589238 | PHASE2 | TERMINATED | 16 | Randomised Phase II Trial of Neoadjuvant Weekly Paclitaxel Plus Carboplatin Comp... |
| NCT03725436 | PHASE1 | ACTIVE_NOT_RECRUITING | 35 | A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 A... |
| NCT01722968 | PHASE2 | COMPLETED | 33 | A Prospective Randomized Phase II Study to Identify Predictive Biomarkers and Me... |
| NCT00499291 | NA | WITHDRAWN | 0 | Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Nab-Paclitaxel (Na... |
| NCT02645175 | PHASE2 | TERMINATED | 3 | A Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the S... |
| NCT04939610 | PHASE1, PHASE2 | RECRUITING | 222 | LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investiga... |
| NCT02685059 | PHASE2 | COMPLETED | 174 | A Randomized Phase II Study to Investigate the Addition of PD-L1 Antibody MEDI47... |
| NCT06371807 | PHASE2 | NOT_YET_RECRUITING | 20 | Immunogenicity Profile of Neoadjuvant Keytruda in Combination With Anthracycline... |
| NCT05503108 | PHASE3 | SUSPENDED | 10 | DIRECT-2: Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in HR+, HER2- B... |
| NCT00038402 | PHASE3 | COMPLETED | 74 | Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuv... |
| NCT00070278 | PHASE3 | UNKNOWN | 800 | A Phase III Randomized Neoadjuvant Study of Sequential Epirubicin/Cyclophosphami... |
| NCT00088829 | PHASE2 | TERMINATED | 22 | A Pilot Study to Establish a Standardized Protocol for Gene Microarray Analysis ... |
| NCT05582499 | PHASE2 | RECRUITING | 716 | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series ... |
| NCT05749575 | PHASE2 | UNKNOWN | 28 | A Prospective, Open-label, Phase II Clinical Trial of Chidamide, PD-1 Monoclonal... |
| NCT01763710 | PHASE2 | COMPLETED | 60 | Neurotoxicity Characterization Phase II Randomized Study of Nab-paclitaxel Versu... |
| NCT05912062 | N/A | UNKNOWN | 80 | Early On-treatment Transcriptional Profiling as Predictor of Response in Early-s... |
| NCT05831553 | N/A | UNKNOWN | 100 | Evaluation of a Tissue Immune Profile (TIP) in Patients Affected by Metastatic T... |
| NCT02069158 | PHASE1 | COMPLETED | 17 | DOSE FINDING STUDY OF PF-05212384 WITH PACLITAXEL AND CARBOPLATIN IN PATIENTS WI... |
| NCT01367288 | PHASE2 | COMPLETED | 53 | Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Manage... |
| NCT00537173 | N/A | TERMINATED | 11 | Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin fo... |
| NCT01973660 | PHASE2 | COMPLETED | 151 | PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadj... |
| NCT01750073 | PHASE2 | ACTIVE_NOT_RECRUITING | 92 | A Phase II Study of Neoadjuvant Chemotherapy With and Without Trastuzumab in Pat... |
| NCT00991263 | N/A | COMPLETED | 3677 | Intrinsic Breast Cancer Subtypes and Benefit of Paclitaxel in CALGB 9344 and Dos... |
| NCT00820690 | N/A | UNKNOWN | 80 | Gene Expression Signature and Immunohistochemical Markers Associated With Respon... |
| NCT06561607 | PHASE3 | NOT_YET_RECRUITING | 542 | A Randomized, Open, Parallel-Controlled Phase III Clinical Trial Evaluating the ... |
| NCT00717340 | PHASE1 | COMPLETED | 18 | A Phase 1b/2a, Open-Label, Multi-Center Study of Tivozanib (AV-951) in Combinati... |
| NCT03168880 | PHASE3 | ACTIVE_NOT_RECRUITING | 720 | A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Pac... |
| NCT02938442 | PHASE1, PHASE2 | COMPLETED | 16 | A Combined Phase i/II Efficacy Study of a Carbohydrate Mimotope-based Vaccine Wi... |
| NCT00486668 | PHASE3 | UNKNOWN | 529 | A Randomized Phase III Trial of Neoadjuvant Therapy for Patients With Palpable a... |
| NCT04248998 | PHASE2 | UNKNOWN | 30 | Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoth... |
| NCT00899509 | N/A | COMPLETED | 1500 | Correlative Studies of ERBB-2/HER-2/NEU and p53 in CALGB Protocol 9344/INT Proto... |
| NCT05233696 | PHASE2 | WITHDRAWN | 0 | Phase II Study of Radiotherapy in Combination With Chemotherapy and Immunotherap... |
| NCT05422794 | PHASE1 | RECRUITING | 57 | A Phase 1b Trial of ZEN003694 (ZEN-3694) With Pembrolizumab and Nab-Paclitaxel i... |
| NCT00436566 | PHASE2 | COMPLETED | 122 | Phase II Study of Cardiac Safety and Tolerability of an Adjuvant Chemotherapy Pl... |
| NCT01501487 | PHASE4 | COMPLETED | 226 | MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I |
| NCT01617668 | PHASE2 | COMPLETED | 209 | A Phase II Multi-center, Open-label, Neoadjuvant, Randomized Study of Weekly Pac... |
| NCT01802970 | PHASE1 | COMPLETED | 10 | Pilot Safety and Blood Immune Cell Transcriptional Profiling Study of Anakinra P... |
| NCT00499083 | PHASE2 | COMPLETED | 17 | Neoadjuvant Intratumoral Injection of Dendritic Cells in Breast Cancer Translati... |
| NCT01796197 | PHASE2 | COMPLETED | 23 | Phase II Trial of Paclitaxel Combined With Trastuzumab and Pertuzumab as Pre-Ope... |
| NCT00336791 | PHASE3 | COMPLETED | 273 | Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expressi... |
| NCT00898690 | N/A | UNKNOWN | 120 | Determination Of FEZ1/LZTS1 Expression As A Predictor Of Response To Taxol |
| NCT03058939 | PHASE2 | WITHDRAWN | 0 | Assessing the REsponse Rate of Weekly Neo-adjuvanT pacliTAxel (Taxol) in Nigeria... |
| NCT03283384 | PHASE2 | ACTIVE_NOT_RECRUITING | 100 | Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Lumin... |
| NCT00503906 | PHASE2 | COMPLETED | 30 | A Phase II Study of Abraxane, Avastin and Gemcitabine for First Line Metastatic ... |
相關文獻（20 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 26372358 | 2016 | Article | Molecular oncology | Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer de... |
| 39400682 | 2024 | Article | Medical oncology (Northwood, L | Glycolytic pathway analysis and gene expression profiles of combination of aloe ... |
| 30426838 | 2018 | Article | Molecular pain | Expression of mitochondrial dysfunction-related genes and pathways in paclitaxel... |
| 36602784 | 2023 | Article | JAMA oncology | Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs ... |
| 27094684 | 2016 | Article | Scientific reports | Genome-wide profiles of methylation, microRNAs, and gene expression in chemoresi... |
| 25000515 | 2014 | Article | Pharmacogenetics and genomics | Gene expression of peripheral blood cells reveals pathways downstream of glucoco... |
| 39375938 | 2024 | Article | Cancer science | Genomic and transcriptomic profiling of pre- and postneoadjuvant chemotherapy tr... |
| 37148401 | 2023 | Article | Naunyn-Schmiedeberg's archives | Exploring the mechanism by which quercetin re-sensitizes breast cancer to paclit... |
| 38999963 | 2024 | Article | International journal of molec | Identification of New Chemoresistance-Associated Genes in Triple-Negative Breast... |
| 35875026 | 2022 | Article | Frontiers in public health | Triple-Negative Breast Cancer Analysis Based on Metabolic Gene Classification an... |
| 39741209 | 2024 | Article | Cellular and molecular life sc | Microtubule acetylation and PERK activation facilitate eribulin-induced mitochon... |
| 34131286 | 2021 | Article | Oncogene | Individualized lncRNA differential expression profile reveals heterogeneity of b... |
| 27420999 | 2016 | Article | Genetics and molecular researc | Molecular-level effects of eribulin and paclitaxel on breast cancer based on dif... |
| 30999914 | 2019 | Article | Molecular cancer | Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregu... |
| 39308141 | 2024 | Article | Clinical cancer research : an | The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant ... |
| 40615664 | 2025 | Article | Scientific reports | Machine learning combined with multi-omics to identify immune-related LncRNA sig... |
| 40350044 | 2025 | Article | Biochimica et biophysica acta. | Characterization and targeting of chemoresistant triple-negative breast cancer s... |
| 38837893 | 2024 | Article | Clinical cancer research : an | Concurrent RB1 Loss and BRCA Deficiency Predicts Enhanced Immunologic Response a... |
| 23923010 | 2013 | Article | PloS one | Prognostic significance of ESR1 gene amplification, mRNA/protein expression and ... |
| 28835684 | 2017 | Article | Scientific reports | Modulation of SOX2 expression delineates an end-point for paclitaxel-effectivene... |
8. nipple carcinoma L2 99.89%
臨床試驗（2 項）
| 試驗編號 | 階段 | 狀態 | 人數 | 主要發現 |
|---|---|---|---|---|
| NCT03875573 | PHASE2 | ACTIVE_NOT_RECRUITING | 147 | Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Pr... |
| NCT00616967 | PHASE2 | ACTIVE_NOT_RECRUITING | 68 | A Multi-Institutional Double-Blind Phase II Study Evaluating Response and Surrog... |
相關文獻（10 篇）
| PMID | 年份 | 類型 | 期刊 | 主要發現 |
|---|---|---|---|---|
| 39233823 | 2024 | Article | Oncology letters | Neoadjuvant chemotherapy for primary invasive ductal carcinoma of the nipple: A ... |
| 33827325 | 2021 | Article | International journal of surgi | Acinic Cell Carcinoma of the Breast: Report of a Case With Immunohistochemical a... |
| 37064212 | 2023 | Article | Case reports in women's health | Ovarian high-grade serous carcinoma with estrogenic manifestations in a postmeno... |
| 29514832 | 2018 | Article | BMJ case reports | Rare case of metaplastic breast cancer in a man. |
| 38741768 | 2024 | Article | Frontiers in medicine | Untypical bilateral breast cancer with peritoneal fibrosis on 18F-FDG PET/CT: ca... |
| 28133220 | 2016 | Article | Gan to kagaku ryoho. Cancer & | [A Case of HER2-Positive Breast Cancer Treated with Nipple-Sparing Mastectomywit... |
| 39682607 | 2024 | Article | Diagnostics (Basel, Switzerlan | Synchronous Primary Metastatic Infra-Mammary Accessory Breast Cancer and Ipsilat... |
| 22083199 | 2011 | Article | Gan to kagaku ryoho. Cancer & | [A case of pagetoid carcinoma of the breast in nearly complete response by prima... |
| 14981568 | 2004 | Article | Zentralblatt fur Gynakologie | [Primary intracystic squamous cell cancer of female breast]. |
| 33468796 | 2020 | Article | Gan to kagaku ryoho. Cancer & | [Treatment Regimens for Breast Cancer in Elderly Patients in Whom the Diagnosis ... |
9. parameningeal embryonal rhabdomyosarcoma L5 99.73%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
10. botryoid-type embryonal rhabdomyosarcoma of the vagina L5 99.73%
目前尚無針對此適應症的專門臨床研究。此為 TxGNN 模型預測結果，需進一步驗證。
台灣上市資訊
Paclitaxel 在台灣有多種製劑核准上市，包括：
- 傳統溶劑型 Paclitaxel 注射劑
- Nab-paclitaxel (白蛋白結合型)
- Paclitaxel 微脂粒注射劑
原適應症已涵蓋乳癌的多種類型。
安全性考量
重要警語
- 過敏反應：傳統製劑含 Cremophor EL，可能導致嚴重過敏反應，需預防給藥
- 骨髓抑制：嗜中性球低下為劑量限制毒性
- 周邊神經病變：累積劑量相關，可能不可逆
- 心臟毒性：與 anthracycline 併用時需注意
常見副作用
| 副作用 | 發生率 |
|---|---|
| 骨髓抑制 | 非常常見 |
| 周邊神經病變 | 常見 |
| 肌肉關節痛 | 常見 |
| 噁心嘔吐 | 常見 |
| 掉髮 | 非常常見 |
藥物交互作用
- CYP3A4 及 CYP2C8 抑制劑：可能增加 paclitaxel 血中濃度
- CYP3A4 誘導劑：可能降低療效
- Anthracyclines：建議先給 paclitaxel 再給 anthracycline
特殊族群
- 肝功能不全：需根據膽紅素及 AST 調整劑量
- 孕婦：禁忌使用
- 老年人：周邊神經病變風險較高
藥物-食物交互作用 (DFI)
資料來源：DDInter 2.0（原文內容請參閱該網站）
葡萄柚汁 🟡 Moderate
- 影響：影響藥物代謝。可能增加藥物血中濃度。
- 建議：需監測療效或不良反應。可能需調整劑量。避免食用葡萄柚或葡萄柚汁。
藥物-草藥交互作用 (DHI)
聖約翰草（貫葉連翹） 🔴 Major
- 影響：聖約翰草降低化療藥物療效
- 建議：化療期間禁用所有草藥補充品
結論與下一步
整體評估
Paclitaxel 對乳癌的預測已獲得最高等級的臨床證據支持：
- 證據等級最高 (L1)：多個 Phase III 臨床試驗證實療效
- 機轉清晰：微管穩定及免疫調節雙重作用
- 臨床應用成熟：已是乳癌標準治療的重要組成部分
- 持續創新：與免疫療法併用的新組合正在研究中
目前臨床定位
| 乳癌亞型 | Paclitaxel 在治療中的角色 |
|---|---|
| 三陰性乳癌 | 第一線化療核心藥物，常與免疫療法併用 |
| HER2+ 乳癌 | 與 trastuzumab 併用的標準方案 |
| ER+/HER2- 乳癌 | 荷爾蒙治療無效後的化療選項 |
| 發炎性乳癌 | 前導化療的重要成分 |
建議行動
- 持續作為標準治療：Paclitaxel 在乳癌治療中的地位已確立
- 關注新組合療法：與 PD-1/PD-L1 抑制劑的併用研究
- 個人化醫療：根據生物標記選擇最適合的治療組合
本報告由 TxGNN 預測系統生成，僅供研究參考，不構成醫療建議。
相關藥物報告
- Benzylpenicillin - 證據等級 L5
- Allopurinol - 證據等級 L5
- Cerliponase Alfa - 證據等級 L5
- Thiamine - 證據等級 L5
- Buprenorphine - 證據等級 L5
用 AI 幫我深入分析
想進一步了解這個藥物的老藥新用潛力嗎？點擊下方按鈕，直接開啟 AI 助手進行分析。
Claude：點擊後會複製提問並開啟新視窗，請按 Ctrl+V（Mac: Cmd+V）貼上
ChatGPT：點擊後直接開啟並自動帶入提問
引用本報告
如需引用本報告，請使用以下格式：
APA 格式：
TwTxGNN. (2026). Paclitaxel老藥新用驗證報告. https://twtxgnn.yao.care/drugs/paclitaxel/
BibTeX 格式：
@misc{twtxgnn_paclitaxel,
title = {Paclitaxel老藥新用驗證報告},
author = {TwTxGNN Team},
year = {2026},
url = {https://twtxgnn.yao.care/drugs/paclitaxel/}
}
免責聲明
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
本報告僅供學術研究參考，不構成醫療建議。藥物使用請遵循醫師指示，切勿自行調整用藥。任何老藥新用決策需經過完整的臨床驗證與法規審查。
最後審核：2026-02-20 | 審核者：TwTxGNN Research Team
歡迎分享您對本報告的看法、補充資訊或提出問題。討論內容會同步到 GitHub Discussions。 需要 GitHub 帳號才能留言。